Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10720319 | 0.83 | L3MBTL1 (0.60) | L3MBTL1TSHRSMN1; SMN2TRPM8ALDH1A1 | |
| SCHEMBL9001748 | 0.77 | TSHR (0.68) | L3MBTL1TSHRSMN1; SMN2TRPM8ALDH1A1 | |
| SCHEMBL4139952 | 0.76 | L3MBTL1 (0.62) | L3MBTL1TSHRALDH1A1LMNAMEN1 | |
| SCHEMBL10720234 | 0.75 | HSD11B1 (0.56) | L3MBTL1TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7286178 | 0.74 | MEN1 (0.46) | ALDH1A1LMNAMEN1KMT2ASLC6A2 | |
| SCHEMBL3094963 | 0.74 | TSHR (0.49) | L3MBTL1TSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10722280 | 0.74 | HSD11B1 (0.70) | L3MBTL1TSHRLMNAMEN1KMT2A | |
| SCHEMBL2225884 | 0.73 | HPGD (0.57) | L3MBTL1TSHRSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL7290560 | 0.73 | MEN1 (0.44) | ALDH1A1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL10726904 | 0.72 | SLC6A4 (0.54) | L3MBTL1TSHRTRPM8LMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| CN-101056865-A | Aminoquinazolines compounds | HOFFMANN LA ROCHE (CH) | 2007-10-17 | — | — | CN | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | L3MBTL1 4442/4885TSHR 3099/4885SMN1; SMN2 4747/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | L3MBTL1 4442/4885TSHR 3099/4885SMN1; SMN2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.